Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).

Hum Vaccin Immunother · 2022 · PMC8920144 · PMID 34726574

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

25–27 , 29 Subgroup analyses showed a trend toward lower pneumococcal immune responses in older adults (65–74 years and ≥75 years) compared with younger adults (50–64 years) in both the concomitant and non-concomitant groups.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.